A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation

被引:26
作者
Alak, A [1 ]
Moy, S [1 ]
Bekersky, I [1 ]
机构
[1] RUSH PRESBYTERIAN ST LUKES MED CTR,RES LAB,FUJISAWA USA INC,CHICAGO,IL 60612
关键词
AmBisome; amphotericin B; high-performance liquid chromatography; pharmacokinetics; amphotericin B assay;
D O I
10.1097/00007691-199610000-00014
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A sensitive and selective high-performance liquid chromatographic (HPLC) method has been developed for the determination of amphotericin B in human serum. After methanol deproteinization, amphotericin B and 3-nitrophenol (internal standard) are separated by reversed-phase chromatography and detected by ultraviolet absorbance. The analysis of human serum after the standard addition of amphotericin B (0.05-200.0 mu g/mL) demonstrated excellent precision and accuracy over a five-day period. The HPLC assay uses two standard curve ranges. The high sensitivity curve range for low AmBisome dosage (1.0 mg/kg) is 0.05-20.0 mu g/mL (curve 1), and the second curve range for the higher AmBisome dose regimens (2.5-5.0 mg/kg) is 0.5-200 mu g/mL (curve 2). The intraday and interday coefficients of variations for standard curve 1 were 0.5-4.6% and 3.0-11.5%, respectively. The limit of quantitation was 0.05 mu g/mL. The intraday and interday coefficients of variation for standard curve 2 were 2.0-3.6 and 6.9-10.1, respectively. No interfering peak at the retention time for Amphotericin B and the internal standard were present in blank serums or serum samples spiked with fifteen potential co-administrated drugs with Amphotericin B treatment. The method was used to quantitate serum concentrations of amphotericin B in patients after the administration of AmBisome, a liposomal formulation of amphotericin B.
引用
收藏
页码:604 / 609
页数:6
相关论文
共 18 条
  • [1] AMPHOTERICIN-B PHARMACOKINETICS IN HUMANS
    ATKINSON, AJ
    BENNETT, JE
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1978, 13 (02) : 271 - 276
  • [2] A REVERSE-PHASE HPLC ASSAY FOR MEASURING THE INTERACTION OF POLYENE MACROLIDE ANTIFUNGAL AGENTS WITH STEROLS
    BACKES, BJ
    RYCHNOVSKY, SD
    [J]. ANALYTICAL BIOCHEMISTRY, 1992, 205 (01) : 96 - 99
  • [3] BHATHENA DB, 1978, CLIN NEPHROL, V9, P103
  • [4] AMPHOTERICIN-B - CURRENT UNDERSTANDING OF MECHANISMS OF ACTION
    BRAJTBURG, J
    POWDERLY, WG
    KOBAYASHI, GS
    MEDOFF, G
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (02) : 183 - 188
  • [5] AMPHOTERICIN-B - DELIVERY SYSTEMS
    BRAJTBURG, J
    POWDERLY, WG
    KOBAYASHI, GS
    MEDOFF, G
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (03) : 381 - 384
  • [6] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF AMPHOTERICIN-B IN HUMAN-SERUM
    BRASSINNE, C
    LADURON, C
    COUNE, A
    SCULIER, JP
    HOLLAERT, C
    COLLETTE, N
    MEUNIER, F
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 419 : 401 - 407
  • [7] BUTLER WT, 1966, JAMA-J AM MED ASSOC, V195, P271
  • [8] SOLUBILITY AND STABILITY OF AMPHOTERICIN-B IN HUMAN-SERUM
    EDMONDS, LC
    DAVIDSON, L
    BERTINO, JS
    [J]. THERAPEUTIC DRUG MONITORING, 1989, 11 (03) : 323 - 326
  • [9] LIPOSOMAL DRUG DELIVERY - ADVANTAGES AND LIMITATIONS FROM A CLINICAL PHARMACOKINETIC AND THERAPEUTIC PERSPECTIVE
    FIELDING, RM
    [J]. CLINICAL PHARMACOKINETICS, 1991, 21 (03) : 155 - 164
  • [10] AMPHOTERICIN-B AND ITS DELIVERY BY LIPOSOMAL AND LIPID FORMULATIONS
    GATES, C
    PINNEY, RJ
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1993, 18 (03) : 147 - 153